Images of WATCHMAN patients surrounding a larger image of a smiling patient.

A lifetime of stroke risk reduction, without the lifelong risks of OACs

Learn more
WATCHMAN Device viewed from above on a light gray background.

One Time. For a Lifetime.

Protection against stroke risk. Protection against oral anticoagulant (OAC) bleed risk.

The WATCHMAN Implant is the one-time, minimally invasive procedure that protects your atrial fibrillation patients for life.


Over 400,000 Afib patients have left blood thinners behind with WATCHMAN LAAC Devices1


400,000+ patients
10+ clinical trials


99% implant success rate*
0.5% major adverse event rate**


96.2% of patients discontinued NOAC at 45 days

Designed to treat a broad range of patient types

Previous bleed

A history of major or non‑major bleeding

Future bleed risk

A high risk of bleeding or at risk for falls

Lifestyle and occupation

Active lifestyle or occupation that poses bleeding risk

Left Atrial Appendage Occlusion Devices Upgraded to a 2a Class of Recommendation for patients with a contraindication to long-term OACs.3

This upgrade in recommended indication is based on additional safety and efficacy data for left atrial appendage occlusion devices, which includes the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Implant.

A 2b Class of Recommendation was added for patients with a high risk of major bleeding.

Protect your patients: Stroke risk reduction without the risks of OACs

Learn more about the WATCHMAN Implant and hear from cardiologists on this safe, OAC alternative for stroke risk reduction.

WATCHMAN Device tilted at angle on white background.

The world's most studied and implanted LAAC device

View real-world and clinical data

Learn more about WATCHMAN

Access resources

Access WATCHMAN Implant resources by visiting our WATCHMAN download center

Stay connected

Receive monthly updates about the WATCHMAN Implant

Rep visit

Connect with a local representative to learn more about the WATCHMAN Implant

One Time. For a Lifetime.

* Procedure success defined as successful delivery and release of a WATCHMAN FLX device into the LAA
** Occurrence of one of the following events between the time of implant and within 7 days following the procedure or by hospital discharge, whichever is later: all-cause death, ischemic stroke, systemic embolism, or device or procedure related events requiring open cardiac surgery or major endovascular intervention.


  1. Represents all WATCHMAN models, including WATCHMAN FLX Devices.
  2. Kar, S., et al, Primary Outcome Evaluation of the Next Generation LAAC Device: Results from the PINNACLE FLX Trial, Circulation, 2021.
  3. Joglar JA et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2024